Stock listing

NASDAQ:ALZN Alzamend Neuro, Inc. Stock

Home listing (NASDAQ) of Alzamend Neuro, Inc.

Follow Alzamend Neuro, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ALZN

$0.776 USD -0.244 (-23.9%)

Close on Nov 20, 2026

Past year -60.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.754 – $1.000 USDNov 20, 2026
Volume
93,200 sharesNov 20, 2026
Market cap
$3.74M USDAt the close on Nov 20, 2026 · price × 4.83M shares outstanding
52-week range
$0.754 – $2.535 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$126,529 USDMedian day 37,400 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Alzamend Neuro, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ALZN · Home$0.776 USD-0.244 (-23.9%)93,200$1.000$1.000$0.754$1.020Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ALZN · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.776-0.244-23.9%$1.000$1.000$0.75493,200
$1.020-0.020-1.9%$1.020$1.205$1.00037,100
$1.040-0.090-8.0%$1.120$1.130$1.01036,300
$1.130-0.050-4.2%$1.180$1.180$1.11720,700
$1.180-0.060-4.8%$1.230$1.298$1.11049,500
$1.240-0.060-4.6%$1.340$1.380$1.22738,800
$1.300-0.010-0.8%$1.290$1.371$1.25023,700
$1.310-0.040-3.0%$1.370$1.445$1.29013,400
$1.350-0.070-4.9%$1.390$1.450$1.33015,900
$1.420+0.010+0.7%$1.440$1.520$1.33061,500
$1.410-0.140-9.0%$1.660$1.660$1.34138,100
$1.550+0.020+1.3%$1.600$1.620$1.50776,000
$1.530+0.070+4.8%$1.535$1.620$1.48072,100
$1.460+0.210+16.8%$1.240$1.526$1.240240,500
$1.250+0.040+3.3%$1.320$1.330$1.21037,100
$1.210-0.010-0.8%$1.290$1.329$1.21025,000
$1.220+0.030+2.5%$1.365$1.365$1.20015,800
$1.190+0.060+5.3%$1.155$1.230$1.12021,400
$1.130-0.010-0.9%$1.170$1.249$1.1108,800
$1.140+0.010+0.9%$1.100$1.155$1.10025,700
$1.130+0.010+0.9%$1.110$1.190$1.10029,100
$1.120-0.130-10.4%$1.250$1.290$1.12015,300
$1.250-0.050-3.8%$1.290$1.390$1.25010,500
$1.300-0.030-2.3%$1.300$1.330$1.28010,900
$1.330+0.030+2.3%$1.340$1.345$1.3106,500
$1.300+0.020+1.6%$1.290$1.340$1.25015,900
$1.280-0.070-5.2%$1.320$1.335$1.28015,000
$1.3500.0000.0%$1.310$1.396$1.31023,200
$1.350+0.040+3.1%$1.430$1.430$1.30018,000
$1.310-0.030-2.2%$1.400$1.429$1.31017,000
$1.3400.0000.0%$1.430$1.430$1.34013,300
$1.340-0.030-2.2%$1.320$1.350$1.2207,000
$1.3700.0000.0%$1.370$1.420$1.34018,800
$1.370-0.040-2.8%$1.435$1.435$1.34332,100
$1.410+0.040+2.9%$1.380$1.480$1.37525,400
$1.370+0.055+4.2%$1.410$1.480$1.200236,400
$1.315-0.415-24.0%$1.720$1.720$1.260150,600
$1.730-0.090-4.9%$1.840$1.840$1.73021,700
$1.820+0.090+5.2%$1.745$1.850$1.74049,500
$1.730-0.100-5.5%$1.800$1.920$1.73083,800
$1.830+0.010+0.5%$1.900$1.900$1.76423,300
$1.820-0.120-6.2%$1.900$1.930$1.820150,500
$1.9400.0000.0%$1.930$1.950$1.93045,800
$1.9400.0000.0%$1.930$1.940$1.90091,200
$1.940+0.050+2.6%$1.890$1.940$1.870206,700
$1.890+0.050+2.7%$1.840$1.890$1.810240,700
$1.840+0.010+0.5%$1.830$1.840$1.82042,700
$1.830+0.050+2.8%$1.790$1.850$1.790167,600
$1.780+0.030+1.7%$1.750$1.790$1.725230,000
$1.750+0.030+1.7%$1.720$1.760$1.70969,100
$1.720+0.020+1.2%$1.670$1.760$1.590393,600
$1.700+0.020+1.2%$1.670$1.700$1.5768,800
$1.6800.0000.0%$1.690$1.730$1.64529,600
$1.680+0.020+1.2%$1.660$1.717$1.62031,200
$1.660-0.040-2.4%$1.700$1.730$1.65063,200
$1.7000.0000.0%$1.650$1.720$1.650128,200
$1.700+0.063+3.8%$1.650$1.700$1.565100,700
$1.637+0.037+2.3%$1.615$1.680$1.61523,300
$1.600-0.060-3.6%$1.655$1.655$1.51037,700
$1.660-0.005-0.3%$1.640$1.720$1.640242,100
$1.665-0.005-0.3%$1.670$1.670$1.65039,700
$1.670+0.070+4.4%$1.590$1.670$1.550125,300
$1.600+0.050+3.2%$1.530$1.650$1.501122,000
$1.550-0.010-0.6%$1.510$1.580$1.410133,800
$1.560-0.070-4.3%$1.570$1.598$1.490242,700
$1.630+0.110+7.2%$1.560$1.670$1.532486,200

Splits

3 splits since 2023 · NASDAQ:ALZN · every price before a split is adjusted for it

DayRatioWhat
1-for-9Consolidation
1-for-10Consolidation
1-for-15Consolidation
Ticker
NASDAQ:ALZN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Alzamend Neuro, Inc. news

Alzamend Neuro, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
6 in the last 12 months · 72 in all · newest Aug 20, 2026 · oldest 2021
Decks
12 decks · latest November 2026

Where Alzamend Neuro, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ALZN · Home listing · This pageNASDAQUnited StatesUSD
BOATS:ALZNBOATSUnited StatesUSD

Valuation

Price/book 0.7× against a median of 0.8×: 4th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Jul 31, 2026 · price Nov 20, 2026

Enterprise value
−$3.85M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.7×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
2.00

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Alzamend Neuro, Inc. · NASDAQ:ALZNUS$3.74M−US$3.85Mn/an/an/a0.7×n/a0.0×2.00
Processa Pharmaceuticals, Inc. · NASDAQ:PCSAUS$4.37M−US$175.8Mn/an/an/an/an/an/a1.60
AdAlta Ltd. · ASX:1ADUS$4.25MUS$3.40Mn/an/an/a17.4×n/a0.0×n/a
Percheron Therapeutics Limited · ASX:PERUS$3.94MUS$1.27Mn/an/an/a0.8×n/a0.0×n/a
Lantern Pharma Inc. · NASDAQ:LTRNUS$3.89M−US$3.69Mn/an/an/a2.8×n/a0.0×2.80
Silo Pharma, Inc. · NASDAQ:SILOUS$3.77M−US$4.28Mn/an/an/a0.5×n/a0.0×1.23
Biotron Limited · ASX:BITUS$3.69MUS$2.66Mn/an/an/a1.9×n/a0.0×n/a
Reviva Pharmaceuticals Holdings, Inc. · NASDAQ:RVPHUS$3.68M−US$13.77Mn/an/an/a0.3×n/a0.0×1.57
Liminatus Pharma, Inc. · NASDAQ:LIMNUS$3.37MUS$1.80Mn/an/an/a11.2×n/a4.8×0.94
Xenetic Biosciences, Inc. · NASDAQ:XBIOUS$3.28M−US$2.53Mn/a−0.8×n/a0.7×−123.7%0.0×1.46
Aprea Therapeutics, Inc. · NASDAQ:APREUS$3.25M−US$34.60Mn/an/an/a0.1×n/a0.0×0.73
Median of the othersUS$3.73M−US$3.11M−0.8×0.8×−123.7%0.0×1.46

Forecasts

1 strong buy · Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.

Price target
26.00 USD · Analysts' mean
EPS, year to Apr 2027
-1.05 · 1 analyst

Team and board

Officers

OfficerRole
Stephan JackmanChief Executive Officer and Director
William B. HorneChairman of Alzamend, Chief Executive Officer of Ault Alliance, Inc.
David J. KatzoffChief Financial Officer
Mark Gustafson C.P.A.Chief Financial Officer of PharmaKure Limited
Henry C.W. NisserExecutive Vice President, General Counsel and Director
Kenneth S. CragunSenior Vice President of Finance
Milton C AultFounder and Vice Chairman of Alzamend

Board

DirectorRole
William B. HorneChairman of Alzamend, Chief Executive Officer of Ault Alliance, Inc.
Henry C.W. NisserExecutive Vice President, General Counsel and Director
Milton C AultFounder and Vice Chairman of Alzamend
Stephan JackmanChief Executive Officer and Director

Events

Next results
Dec 8, 2026 (expected)
QuarterResultsShare move
Q1 2027Sep 10, 2026 · After close+1.2%
Q4 2026Jul 22, 2026 · After close−6.7%
Q3 2026Mar 11, 2026 · After close−4.1%
Q2 2026Dec 9, 2025 · After close−0.5%
Q1 2026Sep 10, 2025 · After close+2.1%
Q4 2025Jul 22, 2025 · After close−5.9%
Q3 2025Mar 10, 2025 · After close−1.6%
Q2 2025Dec 11, 2024 · After close−0.8%
Q1 2025Sep 11, 2024 · After close−0.5%
Q4 2024Jul 27, 2024 · After close+4.7%
All 20 quarters
QuarterResultsShare move
Q3 2024Mar 25, 2024 · After close−1.5%
Q2 2024Dec 15, 2023 · After close0.0%
Q1 2024Sep 13, 2023 · After close−1.3%
Q4 2023Jul 27, 2023 · After close+0.8%
Q3 2023Mar 15, 2023 · After close−4.8%
Q2 2023Dec 12, 2022 · After close−0.9%
Q1 2023Sep 13, 2022 · After close+6.5%
Q4 2022Jul 19, 2022 · After close+2.0%
Q3 2022Mar 15, 2022 · After close+8.9%
Q2 2022Dec 13, 2021 · After close+28.3%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck29 slidesNovember 2026
ISMRM Workshop Advances in X-Nuclei MR 2026Conference17 slidesSep 29, 2026
Investor Presentation (July 2026)Investor deck29 slidesJuly 2026
Investor Presentation (May 2024)Investor deck30 slidesMay 15, 2024
Investor Presentation (April 2023)Investor deck28 slidesApr 25, 2023
Investor Presentation (January 2023)Investor deck27 slidesJan 20, 2023
Investor Presentation (November 2022)Investor deck27 slidesNov 16, 2022
Investor Presentation (August 2022)Investor deck27 slidesAug 15, 2022
Investor Presentation (June 2022)Investor deck27 slidesJun 6, 2022
Investor Presentation (April 2022)Investor deck24 slidesApr 18, 2022
All 12 decks
DeckKindSlidesDate
IPO Roadshow (June 2021)IPO roadshow20 slidesJun 7, 2021
IPO Roadshow (May 2021)IPO roadshow21 slidesMay 28, 2021

Open Decks

Financings

RaiseDate
Series D Convertible Preferred Stock
Tranche closed: US$7.5M raised · US$1,000 a share
Buyers: Ault Lending, LLC (agreed to purchase up to 25,000 Preferred Shares for $25,000,000; purchased 7,500 Preferred Shares for $7,500,000 at the initial closing)
Use of proceeds: General working capital and corporate purposes, including furthering its clinical trials
Aug 4, 2026
Private placement of series C Convertible Preferred Stock and warrants
Closed: private placement
Use of proceeds: To support the five Phase II clinical trials of AL001 Lithium in Brain studies at Massachusetts General Hospital
Jun 16, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$5.00 a share on Jun 14, 2021.

Price
US$5.00 a share
Shares offered
2,500,000 shares of common stock
Offering size
US$12.5 million
Underwriters' option
Up to 375,000 more shares
Listing
ALZN on the Nasdaq Capital Market
Underwriter
Spartan Capital Securities, LLC
Shares delivered
On or about Jun 17, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceDec 29, 2020
Filed publiclyMay 10, 2021
Amended 4 timesNewest Jun 11, 2021
Shares registered with an exchangeJun 11, 2021
Declared effective by the SECJun 14, 2021
Final prospectus, with the priceJun 15, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Jun 15, 2021

Financials

Annual, in USD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020
Research and development3.63M1.41M6.46M7.45M5.20M1.31M1.07M
Operating income-8.77M-4.50M-9.94M-14.9M-12.3M-4.95M-4.42M
Depreciation and amortization110.7K50.7K50.7K23.1K3.55K
EBITDA-8.66M-4.45M-9.89M-14.8M-12.3M
Interest expense6.62K18.0K10.1K7.70K46.5K142.4K
Income before tax-8.77M-4.51M-9.95M-14.9M-12.4M-5.05M-4.41M
Net income-8.77M-4.51M-9.95M-14.9M-12.4M-5.05M-4.41M
Earnings per share, basic-2.63-11.32-132.33-22.89-0.14-0.07-0.06
Earnings per share, diluted-2.63-11.32-132.33-22.89-0.14-0.07-0.06

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents710.7K3.95M376.0K5.14M14.1M1.93M90.3K
Current assets1.76M4.18M455.2K5.84M14.4M2.91M1.81M
Property, plant and equipment314.9K425.6K176.3K79.8K102.9K
Total assets2.08M4.60M631.6K5.92M14.5M2.91M1.81M
Accounts payable2.93M2.87M1.16M503.6K929.6K
Current liabilities2.87M1.16M899.6K992.3K
Total liabilities1.35M634.8K3.23M2.87M1.16M899.6K
Shareholders' equity733.2K3.97M-2.59M3.05M13.4M2.01M821.7K
Shares outstanding4.26M778.7K76.4K646.3K95.5M67.4M64.8M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-8.07M-6.57M-8.27M-8.92M-6.61M-2.71M-2.35M
Cash from investing-300.0K-147.2K-106.5K100.9K105.0K
Cash from financing4.83M10.4M3.65M20018.9M4.45M2.29M
Change in cash-3.24M3.57M-4.76M-8.92M12.1M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 18, 2026Current reportSEC
S-3 · Registration statementNov 17, 2026Offer documentSEC
8-K · Current reportNov 17, 2026Current reportSEC
8-K/A · Current report, amendedNov 10, 2026Material contractSEC
RW · Request to withdraw a registrationOct 9, 2026Other filingsSEC
8-K · Current reportSep 29, 2026Current reportSEC
10-Q · Quarterly reportSep 10, 2026Quarterly reportSEC
4 · Change in ownershipAug 31, 2026Insider tradeSEC
4/A · Change in ownership, amendedAug 31, 2026Insider tradeSEC
4/A · Change in ownership, amendedAug 31, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
PRE 14A · Preliminary proxy statementAug 28, 2026Meeting noticeSEC
S-1 · Registration statementAug 21, 2026Offer documentSEC
4/A · Change in ownership, amendedAug 20, 2026Insider tradeSEC
3/A · Initial statement of ownership, amendedAug 20, 2026Insider tradeSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 4, 2026Insider tradeSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
5 · Annual statement of ownershipAug 4, 2026Insider tradeSEC
5 · Annual statement of ownershipAug 4, 2026Insider tradeSEC
5 · Annual statement of ownershipAug 4, 2026Insider tradeSEC
5 · Annual statement of ownershipAug 4, 2026Insider tradeSEC
5 · Annual statement of ownershipAug 4, 2026Insider tradeSEC
5 · Annual statement of ownershipAug 4, 2026Insider tradeSEC
5 · Annual statement of ownershipAug 4, 2026Insider tradeSEC
8-K · Current reportAug 3, 2026Material contractSEC
10-K · Annual reportJul 22, 2026Annual reportSEC
8-K · Current reportJul 21, 2026Current reportSEC
8-K · Current reportApr 17, 2026Meeting outcomeSEC
4 · Change in ownershipApr 16, 2026Insider tradeSEC
8-K · Current reportMar 20, 2026Current reportSEC
10-Q · Quarterly reportMar 11, 2026Quarterly reportSEC
424B5 · ProspectusMar 6, 2026Offer documentSEC
8-K · Current reportMar 6, 2026Material contractSEC
DEFA14A · Additional proxy materialFeb 26, 2026Meeting noticeSEC
DEF 14A · Proxy statementFeb 26, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementFeb 9, 2026Meeting noticeSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
10-Q · Quarterly reportDec 9, 2025Quarterly reportSEC
8-K · Current reportNov 18, 2025Current reportSEC
4 · Change in ownershipOct 24, 2025Insider tradeSEC
8-K · Current reportOct 14, 2025Current reportSEC
4 · Change in ownershipOct 10, 2025Insider tradeSEC
8-K · Current reportOct 9, 2025FinancingSEC
4 · Change in ownershipOct 8, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 7, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 3, 2025Big-stake noticeSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 30, 2025Big-stake noticeSEC
4 · Change in ownershipSep 30, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 25, 2025Big-stake noticeSEC
4 · Change in ownershipSep 25, 2025Insider tradeSEC
8-K · Current reportSep 25, 2025FinancingSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 23, 2025Big-stake noticeSEC
4 · Change in ownershipSep 23, 2025Insider tradeSEC
4 · Change in ownershipSep 19, 2025Insider tradeSEC
10-Q · Quarterly reportSep 10, 2025Quarterly reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 1, 2025Big-stake noticeSEC
8-K · Current reportAug 1, 2025FinancingSEC
4 · Change in ownershipAug 1, 2025Insider tradeSEC
4 · Change in ownershipJul 29, 2025Insider tradeSEC
4 · Change in ownershipJul 25, 2025Insider tradeSEC
8-K · Current reportJul 23, 2025ResultsSEC
10-K · Annual reportJul 22, 2025Annual reportSEC
144/A · Notice of proposed sale, amendedJul 11, 2025Other filingsSEC
8-K · Current reportJul 9, 2025Current reportSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
144 · Notice of proposed saleMay 9, 2025Other filingsSEC
8-K · Current reportMay 8, 2025Current reportSEC
8-K · Current reportApr 25, 2025Meeting outcomeSEC
424B3 · ProspectusApr 9, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 9, 2025Other filingsSEC
CORRESP · Letter to the SECApr 4, 2025Other filingsSEC
S-1/A · Registration statement, amendedMar 27, 2025Offer documentSEC
4 · Change in ownershipMar 27, 2025Insider tradeSEC
4 · Change in ownershipMar 25, 2025Insider tradeSEC
4 · Change in ownershipMar 24, 2025Insider tradeSEC
UPLOAD · Letter from the SECMar 21, 2025Other filingsSEC
4 · Change in ownershipMar 20, 2025Insider tradeSEC
DEFA14A · Additional proxy materialMar 19, 2025Meeting noticeSEC
4 · Change in ownershipMar 19, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
DEFA14A · Additional proxy materialMar 17, 2025Meeting noticeSEC
4 · Change in ownershipMar 14, 2025Insider tradeSEC
DEF 14A · Proxy statementMar 13, 2025Meeting noticeSEC
S-3 · Registration statementMar 13, 2025Offer documentSEC
10-Q · Quarterly reportMar 10, 2025Quarterly reportSEC
8-K · Current reportMar 3, 2025Current reportSEC
PRE 14A · Preliminary proxy statementFeb 28, 2025Meeting noticeSEC
8-K · Current reportFeb 28, 2025Material contractSEC
8-K · Current reportDec 12, 2024ResultsSEC
10-Q · Quarterly reportDec 11, 2024Quarterly reportSEC
8-K · Current reportOct 15, 2024Current reportSEC
424B5 · ProspectusOct 3, 2024Offer documentSEC
8-K · Current reportOct 3, 2024Material contractSEC
10-Q · Quarterly reportSep 11, 2024Quarterly reportSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 1, 2024Insider tradeSEC
8-K · Current reportJul 31, 2024Current reportSEC
10-K · Annual reportJul 30, 2024Annual reportSEC
NT 10-K · Late filing noticeJul 30, 2024Explanation requestSEC
8-K · Current reportJul 12, 2024Current reportSEC
424B3 · ProspectusJul 10, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveJul 10, 2024Other filingsSEC
8-K · Current reportJul 8, 2024Meeting outcomeSEC
CORRESP · Letter to the SECJul 8, 2024Other filingsSEC
S-1/A · Registration statement, amendedJul 3, 2024Offer documentSEC
CORRESP · Letter to the SECJul 3, 2024Other filingsSEC
UPLOAD · Letter from the SECJul 2, 2024Other filingsSEC
S-1/A · Registration statement, amendedJun 26, 2024Offer documentSEC
CORRESP · Letter to the SECJun 26, 2024Other filingsSEC
UPLOAD · Letter from the SECJun 14, 2024Other filingsSEC
DEFA14A · Additional proxy materialJun 11, 2024Meeting noticeSEC
S-1 · Registration statementJun 3, 2024Offer documentSEC
DEF 14A · Proxy statementMay 31, 2024Meeting noticeSEC
8-K · Current reportMay 22, 2024Current reportSEC
5 · Annual statement of ownershipMay 16, 2024Insider tradeSEC
8-K · Current reportMay 15, 2024Current reportSEC
8-K · Current reportMay 13, 2024Current reportSEC
PRE 14A · Preliminary proxy statementMay 10, 2024Meeting noticeSEC
8-K/A · Current report, amendedMay 10, 2024Material contractSEC
424B5 · ProspectusMay 10, 2024Offer documentSEC
8-K · Current reportMay 9, 2024Material contractSEC
8-K · Current reportMay 9, 2024Current reportSEC
424B5 · ProspectusMay 7, 2024Offer documentSEC
8-K · Current reportMay 7, 2024Current reportSEC
DEFA14A · Additional proxy materialMay 1, 2024Meeting noticeSEC
8-K · Current reportMay 1, 2024Meeting outcomeSEC
8-K · Current reportApr 30, 2024Material contractSEC
4 · Change in ownershipApr 23, 2024Insider tradeSEC
4 · Change in ownershipApr 3, 2024Insider tradeSEC
4 · Change in ownershipApr 1, 2024Insider tradeSEC
8-K · Current reportMar 29, 2024Material contractSEC
4 · Change in ownershipMar 28, 2024Insider tradeSEC
10-Q · Quarterly reportMar 25, 2024Quarterly reportSEC
DEF 14A · Proxy statementMar 25, 2024Meeting noticeSEC
8-K · Current reportMar 22, 2024Material contractSEC
NT 10-Q · Late filing noticeMar 18, 2024Explanation requestSEC
PRE 14A · Preliminary proxy statementMar 13, 2024Meeting noticeSEC
8-K · Current reportMar 7, 2024Current reportSEC
SC 13D/A · Big-stake notice, amendedFeb 2, 2024Big-stake noticeSEC
8-K · Current reportFeb 2, 2024Material contractSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedJan 25, 2024Big-stake noticeSEC
4 · Change in ownershipJan 25, 2024Insider tradeSEC
4 · Change in ownershipJan 9, 2024Insider tradeSEC
8-K · Current reportJan 5, 2024Management or board changeSEC
4 · Change in ownershipDec 27, 2023Insider tradeSEC
10-Q · Quarterly reportDec 15, 2023Quarterly reportSEC
8-K · Current reportNov 16, 2023Current reportSEC
8-K · Current reportOct 30, 2023Current reportSEC
8-K · Current reportSep 29, 2023Meeting outcomeSEC
4 · Change in ownershipSep 26, 2023Insider tradeSEC
8-K · Current reportSep 22, 2023Current reportSEC
10-Q · Quarterly reportSep 13, 2023Quarterly reportSEC
424B5 · ProspectusSep 8, 2023Offer documentSEC
8-K · Current reportSep 8, 2023Material contractSEC
DEFA14A · Additional proxy materialSep 1, 2023Meeting noticeSEC
DEF 14A · Proxy statementAug 24, 2023Meeting noticeSEC
8-K · Current reportAug 16, 2023Current reportSEC
EFFECT · Notice that a registration is effectiveAug 11, 2023Other filingsSEC
PRE 14A · Preliminary proxy statementAug 10, 2023Meeting noticeSEC
CORRESP · Letter to the SECAug 8, 2023Other filingsSEC
UPLOAD · Letter from the SECAug 8, 2023Other filingsSEC
8-K · Current reportAug 7, 2023Current reportSEC
S-3 · Registration statementAug 2, 2023Offer documentSEC
10-K · Annual reportJul 27, 2023Annual reportSEC
8-K · Current reportJun 22, 2023Current reportSEC
4 · Change in ownershipMay 26, 2023Insider tradeSEC
4 · Change in ownershipMay 2, 2023Insider tradeSEC
8-K · Current reportApr 26, 2023Meeting outcomeSEC
8-K · Current reportApr 25, 2023Current reportSEC
8-K · Current reportApr 3, 2023Current reportSEC
DEF 14A · Proxy statementMar 31, 2023Meeting noticeSEC
4 · Change in ownershipMar 23, 2023Insider tradeSEC
8-K · Current reportMar 22, 2023Current reportSEC
4 · Change in ownershipMar 20, 2023Insider tradeSEC
8-K · Current reportMar 16, 2023ResultsSEC
10-Q · Quarterly reportMar 15, 2023Quarterly reportSEC
4 · Change in ownershipFeb 28, 2023Insider tradeSEC
4 · Change in ownershipFeb 17, 2023Insider tradeSEC
8-K · Current reportFeb 3, 2023Current reportSEC
8-K · Current reportJan 20, 2023Current reportSEC
4 · Change in ownershipDec 29, 2022Insider tradeSEC
4 · Change in ownershipDec 23, 2022Insider tradeSEC
4 · Change in ownershipDec 20, 2022Insider tradeSEC
10-Q · Quarterly reportDec 12, 2022Quarterly reportSEC
4 · Change in ownershipNov 30, 2022Insider tradeSEC
4 · Change in ownershipNov 30, 2022Insider tradeSEC
4 · Change in ownershipNov 30, 2022Insider tradeSEC
4 · Change in ownershipNov 30, 2022Insider tradeSEC
4 · Change in ownershipNov 21, 2022Insider tradeSEC
8-K · Current reportNov 16, 2022Current reportSEC
4 · Change in ownershipNov 15, 2022Insider tradeSEC
SC 13D/A · Big-stake notice, amendedNov 15, 2022Big-stake noticeSEC
4 · Change in ownershipNov 3, 2022Insider tradeSEC
4 · Change in ownershipNov 1, 2022Insider tradeSEC
8-K · Current reportOct 31, 2022Current reportSEC
4 · Change in ownershipOct 14, 2022Insider tradeSEC
4 · Change in ownershipOct 7, 2022Insider tradeSEC

This page holds 200 of 401 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Alzamend Neuro, Inc.’s releases · as of Sep 10, 2026

Common shares
4,825,723
Fully diluted
4,825,723

Fully diluted

LineSharesAs of
Common shares4,825,723Sep 10, 2026

Share count over time

CountShares
Sep 10, 20264,825,723

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Kingsbury Capital Investment Advisors LLC1.12M23.2%US$1.94MSep 30, 2026
Citadel79,2181.6%US$137KSep 30, 2026
Vanguard57,2241.2%US$98,998Sep 30, 2026
Jane Street34,3940.71%US$59,501Sep 30, 2026
Hrt Financial LP29,2720.61%US$50,000Sep 30, 2026
Geode Capital26,2640.54%US$45,436Sep 30, 2026
State Street10,9030.23%US$18,862Sep 30, 2026
UBS3,0340.06%US$5,249Sep 30, 2026
Tower Research Capital LLC (TRC)2,2270.05%US$3,853Sep 30, 2026
BlackRock437<0.01%US$756Sep 30, 2026
All 14 holders
HolderSharesOf the companyValueAs of
SBI Securities Co., Ltd.22<0.01%US$38Sep 30, 2026
IFG Advisory, LLC22<0.01%US$38Sep 30, 2026
Caitong International Asset Management Co., Ltd4<0.01%US$7Sep 30, 2026
Harbor Investment Advisory, LLC1<0.01%US$2Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Fidelity Extended Market Index Fund33,5020.69%US$39,867May 31, 2026
Vanguard Extended Market Index Fund7,5560.16%US$9,067Jun 30, 2026
Fidelity Series Total Market Index Fund4,6440.10%US$5,526May 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Ault Milton C III
Director
Sale2,000USD 1.56US$3,120Aug 26, 2026
Ault Milton C III
Director
Buy108,388USD 1.00US$108KApr 14, 2026
Ault Milton C III
Director
Buy2,000USD 1.03US$2,060Apr 14, 2026
Ault Milton C III
Director
Buy108,388USD 1.00US$108KApr 14, 2026

Big stakes

StakeStakeSharesDateFiling
MILTON C. AULT, III4.40%167KOct 3, 2025Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Henry C.W. Nisser
Other companies: Universal Safety Products, Inc. (Director · Since at least Oct 20, 2025); Hyperscale Data, Inc. (General Counsel · Since at least May 1, 2019); Algorhythm Holdings, Inc. (Director · Apr 5, 2023 – Aug 2, 2024 · Past); TurnOnGreen, Inc (Chief Executive Officer, Director · Dec 16, 2021 – Dec 16, 2021 · Past); Ault Disruptive Technologies Corp (President and General Counsel, Director · Dec 15, 2021 – Dec 15, 2021 · Past)
Executive Vice President, General Counsel and Director · Since at least Jun 14, 2021
Milton C Ault III
Other companies: Universal Safety Products, Inc. (Director · Since at least Jul 29, 2025); Hyperscale Data, Inc. (Executive Chairman, Director · Since at least Oct 20, 2023); Ault Disruptive Technologies Corp (Director · Sep 30, 2024 – Sep 30, 2024 · Past); RiskOn International, Inc. (Chief Executive Officer, Director · Jan 23, 2024 – Apr 24, 2024 · Past)
Director · Since at least Jan 5, 2024
David J. Katzoff
Other companies: TurnOnGreen, Inc (CFO, Secretary, Treasurer · Dec 16, 2021 – Jun 26, 2023 · Past); Ault Disruptive Technologies Corp (Vice President - Finance · Dec 15, 2021 – Dec 15, 2021 · Past)
Chief Financial Officer · Since at least Jun 14, 2021
Mark Gustafson C.P.A.
Other companies: Ault Disruptive Technologies Corp (Director · Dec 15, 2021 – Dec 15, 2021 · Past); Triangle Petroleum Corporation (Chief Executive Officer, Director · Jan 16, 2007 – Oct 30, 2009 · Past)
Chief Financial Officer of PharmaKure Limited · Since at least Jun 14, 2021
Kenneth S. Cragun
Other companies: Hyperscale Data, Inc. (Chief Financial Officer · Since at least Sep 4, 2026)
Senior Vice President of Finance · Since at least Nov 5, 2026
William B. Horne
Other companies: Hyperscale Data, Inc. (Chief Executive Officer, Director · Since at least Dec 30, 2024)
Director · Since at least Mar 18, 2025
Andrew H WooDirector · Jun 14, 2021 – Mar 15, 2022 · Past
Escalona LienChief Financial Officer · Jun 14, 2021 – Jun 14, 2021 · Past
Jeffrey OramDirector · Since at least Jun 14, 2021
Lynne Fahey McGrathDirector · Since at least Jun 14, 2021
All 12 people
PersonSeat
Milton C AultFounder and Vice Chairman of Alzamend · Since at least Aug 4, 2026
Stephan JackmanChief Executive Officer and Director · Since at least Jun 14, 2021

Open People

Log in to ask 6ix AI your own questions about Alzamend Neuro, Inc.